BioNTech (BNTX) has entered into two separate settlements with the US National Institutes of Health and the University of Pennsylvania over royalties on sales of the company's Covid-19 vaccine, separate filings showed Friday.
Without admitting liability, the biotechnology company said it agreed to pay $791.5 million to the NIH and $467 million to UPenn for, among others, claimed royalties from 2020 to 2023, according to the filings.
BioNTech also said Pfizer (PFE) agreed to reimburse $364.5 million of NIH's claimed royalties and up to $170 million of the amount payable to UPenn.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。